文献速递乳腺癌放疗姑息放疗与转移瘤

立体定向体部放疗在寡进展乳腺癌中的作用:前瞻性II期RADIANT试验的按部位分析

The role of stereotactic body radiotherapy in oligoprogressive breast cancer: A site-specific analysis of the prospective, phase-II RADIANT trial.
PubMed 文献 · Clin Transl Radiat Oncol · 2026-04-06

RADIANT是一项单臂II期篮式试验,纳入30例接受系统治疗≥3个月的寡进展转移性乳腺癌患者,对最多5个影像学进展转移灶行1-5次SBRT。1年系统治疗改变累积发生率为30.0%,2年为50.4%;1年局部控制率90.0%,无归因于SBRT的≥3级不良事件,健康相关生活质量维持。

要点

  • 寡进展乳腺癌接受SBRT后1年系统治疗改变累积发生率为30.0%。
  • 1年局部控制率90.0%,无归因于SBRT的≥3级不良事件。
  • 健康相关生活质量在整个随访期维持。

核心结论

  • 在寡进展乳腺癌患者中,SBRT是安全且有前景的干预,可能延迟下一线系统治疗。

研究设计与样本

  • RADIANT(NCT04122469)为单臂II期篮式试验,纳入30例接受系统治疗≥3个月的寡进展转移性乳腺癌患者,对最多5个影像学进展转移灶行1-5次SBRT。

主要发现

  • 中位年龄60.0岁,80%为浸润性导管癌,90%为雌激素受体(ER)阳性。
  • 63.3%为复发转移性疾病,36.7%为新发转移性疾病,66.7%接受一线系统治疗。
  • 中位随访33.7个月(范围2.5-57.2个月)。
  • 1年系统治疗改变累积发生率为30.0%(95% CI,17.2-52.4%),2年为50.4%(95% CI,34.9-72.8%)。
  • 1年局部控制率90.0%,远处控制率56.7%。

关键数值与推荐

  • 主要终点为系统治疗改变的累积发生率。
  • 次要终点包括局部控制、无进展生存、总生存、不良事件和健康相关生活质量。

临床怎么用

  • 对接受系统治疗≥3个月的寡进展转移性乳腺癌患者,可考虑对进展灶行SBRT以延迟下一线系统治疗。

局限性

  • 相当比例患者在SBRT后1-2年内仍需改变系统治疗,需生物标志物优选获益人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Standard-of-care management for patients with progressive metastatic breast cancer is changing systemic therapy lines. For patients with limited disease progression ('oligoprogression'), there is interest in treating progressive sites with stereotactic body radiation therapy (SBRT) whilst maintaining the current systemic therapy. Here we report on the clinical, quality of life (QOL) and adverse event findings for a cohort of patients with oligoprogressive breast cancer enrolled on the prospective, phase-II RADIANT clinical trial. METHODS: RADIANT (NCT04122469) was a single-arm, phase-II basket trial which included patients with oligoprogressive metastatic breast cancer. Patients on systemic therapy for ≥ 3 months received SBRT over 1-5 fractions, targeting up to 5 metastases with radiographic progression. The primary endpoint was cumulative incidence of change in systemic therapy. Secondary endpoints included local control, progression-free survival, overall survival, adverse events and health-related (HR) QOL. Analysis by disease histology was planned a priori. RESULTS: Thirty patients were enrolled and analyzed; the median age was 60.0 years, 80% had invasive ductal carcinoma and 90% were estrogen-receptor (ER)-positive. Most patients had recurrent metastatic disease (63.3%), while 36.7% had de novo metastatic disease. Most patients were on first-line (66.7%) systemic therapy. Median follow-up time was 33.7 months (range 2.5-57.2 months). The cumulative incidence of change in systemic therapy at 1-year was 30.0% (95% CI, 17.2-52.4%) and at 2-years was 50.4% (95% CI, 34.9-72.8%). At 1-year, local control rate was 90.0% and distant control rate was 56.7%. There were no grade ≥ 3 adverse events attributable to SBRT. HRQOL was maintained throughout the follow-up period. CONCLUSION: Among this cohort of patients with oligoprogressive breast cancer, SBRT is a safe and promising intervention, with potential to delay next-line systemic therapy. However, as a significant cohort of patients do require a change in systemic therapy within 1-2 years of SBRT, biomarkers are needed to best select patients who would benefit clearly from this approach.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Ruicci KM, Helou J, Barry A, et al. The role of stereotactic body radiotherapy in oligoprogressive breast cancer: A site-specific analysis of the prospective, phase-II RADIANT trial. Clin Transl Radiat Oncol. 2026. PMID: 42011409. doi:10.1016/j.ctro.2026.101164

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。